Usa India covid-19 pandemic Usa India

Dr Reddy’s Q4 ship is steady, but margin expansion remains key to profitability

Reading now: 447
www.livemint.com

As some pharmaceutical companies have shown, covid-19 times are tough. But Dr Reddy’s Laboratories Ltd’s results exhibit that pharma companies can still pull through quite nicely.

Steady performance in the fourth quarter in all its divisions drove its shares up 5.7% on Wednesday. However, future gains will hinge heavily on how the company can further drive margin expansion While the results were just a step ahead of analysts’ expectations, the fact that the company is focusing on sturdy improvements in operations is being seen as key to growth.

In fact, overall revenues in Q4 were up 1.1% quarter-on-quarter. Growth in some key markets such as the US is encouraging. Notably, its North American Q4 revenues rose about 13% q-o-q following

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA